Form 4: Revolution Medicines Director Clyburn Acquires Stock and Options
SEC Form 4 Filing
Frank Clyburn, a director at Revolution Medicines, acquired shares and options in the company on August 5, 2024.
Summary
- On August 5, 2024, Frank Clyburn, a director of Revolution Medicines, acquired 6,932 shares of common stock and options to purchase 27,744 shares.
- The common stock was acquired at a price of $0.
- The options have an exercise price of $42.48 and expire on August 5, 2034.
- The options vest monthly over three years from August 5, 2024.
Sentiment
Score: 6
Explanation: Insider buying is generally viewed as a positive signal, suggesting confidence in the company's prospects, but it's a routine transaction.
Positives
- A director's acquisition of company stock and options can be seen as a positive sign of confidence in the company's future prospects.
Industry Context
This is a standard SEC Form 4 filing, which is common for corporate insiders who have transactions in their company's stock. It provides transparency to the market about insider activity.
Stakeholder Impact
- The acquisition of shares and options by a director could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 08/05/2024 | Date of transaction: Acquisition of common stock and stock options. |
| 08/05/2024 | Options begin to vest monthly over 3 years. |
| 08/05/2034 | Expiration date of the stock options. |
| 08/07/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.